Abstract | BACKGROUND: METHODS: Microalbuminuria was measured on 2 to 3 occasions by using timed overnight samples at baseline and yearly thereafter in 314 DAIS participants (77 women, 237 men; average age, 56 years); all except 3 participants had either a normal albumin excretion rate (<20 microg/min; n = 214) or microalbuminuria ( albumin, 20 to 200 microg/min; n = 97) before randomization. Tabulated shifts (between normal, microalbuminuria, and macroalbuminuria) from baseline to last observed values were compared between treatment groups by means of chi-square or Fisher's exact test. RESULTS:
Fenofibrate significantly reduced the worsening of albumin excretion ( fenofibrate, 8% versus placebo, 18%; P < 0.05). This effect was caused mostly by reduced progression from normal albumin excretion to microalbuminuria: 3 of 101 participants in the fenofibrate group versus 20 of 113 participants in the placebo group (P < 0.001). Overall, changes in albumin excretion were independent of age or changes in lipid or creatinine levels, weight, or blood pressure. CONCLUSION:
|
Authors | Jean-Claude Ansquer, Christelle Foucher, Stephanie Rattier, Marja-Riitta Taskinen, George Steiner, DAIS Investigators |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 45
Issue 3
Pg. 485-93
(Mar 2005)
ISSN: 1523-6838 [Electronic] United States |
PMID | 15754270
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin-Converting Enzyme Inhibitors
- Antihypertensive Agents
- Glycated Hemoglobin A
- Hypolipidemic Agents
- Homocysteine
- Fibrinogen
- Creatinine
- Fenofibrate
|
Topics |
- Albuminuria
(epidemiology, prevention & control)
- Angiotensin II Type 1 Receptor Blockers
(therapeutic use)
- Angiotensin-Converting Enzyme Inhibitors
(therapeutic use)
- Antihypertensive Agents
(therapeutic use)
- Blood Pressure
- Body Mass Index
- Creatinine
(blood)
- Diabetes Mellitus, Type 2
(complications)
- Diabetic Nephropathies
(epidemiology, prevention & control)
- Disease Progression
- Double-Blind Method
- Female
- Fenofibrate
(administration & dosage, therapeutic use)
- Fibrinogen
(analysis)
- Follow-Up Studies
- Glycated Hemoglobin
(analysis)
- Homocysteine
(blood)
- Humans
- Hyperlipidemias
(complications, drug therapy)
- Hypertension
(complications, drug therapy)
- Hypolipidemic Agents
(administration & dosage, therapeutic use)
- Incidence
- Male
- Middle Aged
- Models, Biological
- Smoking
(epidemiology)
- Treatment Outcome
|